Gleason score predicts androgen independent progression after androgen deprivation therapy (Q74471942)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

title

Gleason score predicts androgen independent progression after androgen deprivation therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

E A Benaim

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

C M Pace

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

C G Roehrborn

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

12-17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

Leuprolide with and without flutamide in advanced prostate cancer

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Biological determinants of cancer progression in men with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

The role of watchful waiting in the management of localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2802%2900238-5

7 January 2021

10.1016/S0302-2838(02)00238-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12121723%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference